Current and future use of hematopoietic growth factors in cancer medicine.
AuthorsMughal, Tariq I
AffiliationCRC Division of Medical Oncology, Christie Hospital & Institute of Cancer Research, University of Manchester School of Medicine, Manchester, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractMyelosuppression, in particular neutropenia and anemia are serious complications of malignancy and its treatment. Neutropenia can make patients vulnerable to potentially life-threatening infection. It often results in dose reductions and delay of planned chemotherapy, which can have a significant detrimental effect on tumour response and survival. Anemia can be associated with a range of debilitating effects, which can severely impair patients' QOL. In addition, there is some evidence recognizing anemia as a poor prognostic indicator, associated with reduced treatment efficacy. Reduction in the duration and severity of neutropenia and anemia is possible by initiation of appropriate growth factors during the first and subsequent cycles of chemotherapy. New and improved growth factor support with agents such as pegfilgrastim and darbepoetin alfa has the potential to improve the management of chemotherapy-induced neutropenia and anemia further. Thrombopoietin is currently in clinical trials to assess its potential role in the treatment of thrombocytopenia in patients with cancer.
CitationCurrent and future use of hematopoietic growth factors in cancer medicine. 2004, 22 (3):121-34 Hematol Oncol
- Future directions with hematopoietic growth factors.
- Authors: Vadhan-Raj S
- Issue date: 2003 Jan
- Pegfilgrastim use during chemotherapy: current and future applications.
- Authors: Wolf T, Densmore JJ
- Issue date: 2004 Nov
- Hematopoietic growth factors as supportive therapy for cancer- and chemotherapy-induced conditions.
- Authors: Symann M
- Issue date: 1991 Aug
- Managing hematologic toxicities.
- Authors: Capo G, Waltzman R
- Issue date: 2004 Jan-Feb
- Optimizing the management of chemotherapy-induced neutropenia.
- Authors: Dale DC
- Issue date: 2003 Nov